Biosimilars bills fail in Miss.

02/11/2013 | Pharmalot.com

Bills that would have restricted pharmacists' ability to substitute biosimilar drugs for brand-name therapies failed to advance out of committees in the Mississippi House and Senate. Proponents say that pharmacists should be allowed to substitute only a biosimilar FDA-approved as "interchangeable" with the brand-name biologic drug for the specific indication and that doctors' orders to dispense as written should override payer policies. Opponents say the federal Public Health Service Act allows automatic substitution and the Mississippi legislation and other bills like it are simply an effort to protect drugmaker profits.

View Full Article in:

Pharmalot.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
PacificSource
Boise, ID